SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure 1. *$Fbn1^{C1039G/+}$ hearts display normal cardiac function in the absence of hemodynamic stress.* A. Echocardiographic quantification of cardiac dimensions and function in *$Fbn1^{+/+}$* and *$Fbn1^{C1039G/+}$* mice with and without valvular regurgitation at 4 and 12 months of age. EDD, end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening; LVM, left ventricular mass. n>=14 per group. *p<0.05, **, p<0.01, ***p<0.001, 2w ANOVA, Tukey's correction. B. Representative PV loop of a 12mo *$Fbn1^{+/+}$* (blue line, blue fill) and *$Fbn1^{C1039G/+}$* mouse (red line, red fill) without valvular regurgitation. Summary data obtained from PV loop analysis shown in bar graphs: E_{es}, end-systolic elastance and PRSW, preload recruitable stroke work, reflect load-independent indices of ventricular contractility. Tau, relaxation time constant reflects a load-independent index of ventricular stiffness; n=3-6 per group. C. dP/dt_{max}, peak rate of left ventricular pressure rise, an index of contractility; dP/dt_{min}, peak rate of left ventricular pressure decline, an index of lusitropy. Invasive blood pressure measurements taken from PV loop analysis of *$Fbn1^{+/+}$* and *$Fbn1^{C1039G/+}$* mice without valvular regurgitation at 4 and 12 months of age. n=3-6 per group. D. Gross morphometric analysis of post-natal *$Fbn1^{+/+}$*, *$Fbn1^{C1039G/+}$*, *$Fbn1^{C1039G/C1039G}$* mice at 8do, 6mo and 12mo age, in mice without valvular regurgitation. HW/BW, heart weight/body weight ratio; HW/TL, heart weight/tibial length ratio. n>=4 per group.

Supplemental Figure 2. *$Fbn1^{C1039G/+}$ hearts have normal TGFβ signaling in the absence of hemodynamic stress.* A-C. Representative Western blot and summary quantification for phosphorylated/total (p/t), p/tSmad2, p/tERK1/2, and GAPDH using left ventricular tissue lysates. n=4 per group. D. mRNA expression normalized to *18S* and then to *$Fbn1^{+/+}$* data, assessed by real-time RT-PCR from left ventricular tissue of 3mo *$Fbn1^{+/+}$*and

Fbn$^{/C1039G/+}$ hearts without regurgitation. *Ctgf*, connective tissue growth factor. *Serpine1*, plasminogen activator inhibitor, type 1. n>=4 per group.

Supplemental Figure 3. *Fbn1*$^{C1039G/+}$ *hearts develop hypertrophy and fibrosis in response to pressure overload.* A. Baseline echocardiographic quantification of cardiac dimensions in 5mo *Fbn1*$^{+/+}$ and *Fbn1*$^{C1039G/+}$ mice without valvular regurgitation. EDD, end-diastolic diameter; ESD, end-systolic diameter; IVST, interventricular septum thickness; PWT, posterior wall thickness. n=4-6 per group. B. Myocyte hypertrophy, as assessed by cross-sectional area (CSA) in hematoxylin-eosin staining. Summary quantification of averaged data, >20 cells per heart. n=4 per group. C. Fibrotic area, as assessed by Masson's Trichrome stain and quantified by total number of blue pixels normalized to whole tissue area and then to *Fbn1*$^{+/+}$:SHAM data. n=4-6 per group. D. mRNA expression of hypertrophy genes, normalized to *Gapdh* and then to *Fbn1*$^{+/+}$:SHAM data, assessed by real-time RT-PCR. n=4-6 per group. *Myh7*, myosin heavy chain 7 (βMHC), *Nppa*, natriuretic peptide *A* (ANP), *Nppb*, natriuretic peptide B (BNP). **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 4. *Fibrillin-1 protein fails to deposit in myocardium in load-induced heart failure in Fbn1*$^{C1039G/+}$ *mice.* Additional representative images of immunofluorescent fibrillin-1 staining (red) of heart sections from *Fbn1*$^{+/+}$ and *Fbn1*$^{C1039G/+}$ mice subjected to 4w TAC. Red, fibrillin-1 (interstitial space); blue, DAPI (nuclei); Green, lipofuscin (myocytes). Top 4 panels, Scale bar: 20 μm. Bottom 4 panels, 2x zoom. White arrow head points to an example nonmyocyte cell in the interstitial space.

Supplemental Figure 5. *Smad2 and ERK1/2 activation are differentially increased in the myocyte and nonmyocyte compartments of failing Fbn1*$^{C1039G/+}$ *hearts.* A. Representative serial sections of pSmad2 (red, top panels) and pERK1/2 (red, bottom panels) immunostaining in *Fbn1*$^{C1039G/+}$

hearts subjected to 4w TAC. Far left panels, scale bar: 50 μm. Middle and far right panels, zoom 2x. Blue, DAPI (nuclei); Green, lipofuscin (myocytes). White arrows, myocyte nuclei. Yellow arrows, nonmyocyte nuclei. B. Summary quantification of % of total pSmad2 and pERK1/2 immunofluorescence intensity localized to nonmyocyte (NM) and myocyte (M) cells per unit area. n=10-15 areas quantified. *p<0.05, **p<0.01, Student's t-test. C. Representative myocyte-enriched serial sections. Scale bar: 50 μm. D. Representative co-immunostaining of serial sections with vimentin (yellow) and pSmad2 (left panel) and vimentin (yellow) and pERK1/2 (right panel). Scale bar: 25 μm. Gray, lipofuscin (myocytes).

Supplemental Figure 6. *ERK1/2 activation, but not Smad2 activation, is significantly attenuated by MEK inhibition.* Immunoblot for pSmad2, pERK1/2 and GAPDH using cultured neonatal rat cardiac fibroblasts with TGF-ß3 (10 ng/ml) stimulation for 15 minutes with and without treatment with MEKi, RDEA119 (100nM) or PD98059 (50μM). n=4 per group. **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 7. *Myocyte hypertrophy in Fbn1$^{C1039G/+}$hearts is prevented with losartan and MEKi treatment.* A. Representative hematoxylin-eosin staining of formalin-fixed heart sections. White dotted line delineates myocyte diameter. Scale bars: 50μm. B. Myocyte hypertrophy as assessed by wheat germ agglutinin (WGA) staining. Scale bars: 25μm. C. Summary quantification of average cross-sectional area (CSA) data, >1000 cells per heart. n=4-7 per group. D. mRNA expression of hypertrophy genes, normalized to *Gapdh* and then to *Fbn1*$^{+/+}$:SHAM data, assessed by real-time RT-PCR. *Myh7,* myosin heavy chain 7 (βMHC), Myh6, myosin heavy chain 6 (αMHC), *Nppa,* natriuretic peptide *A* (ANP), *Nppb,* natriuretic peptide B (BNP). n=4-7 per group. *p<0.05, **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 8. *Smad2 and ERK1/2 activation are differentially increased in response to TGFβ and angiotensin II in cardiac fibroblasts.* Immunoblot for pSmad2, pERK1/2 and GAPDH using cultured neonatal murine cardiac fibroblasts with TGFß1 (5 ng/ml) or AngII (5nM) stimulation for 24 hours. Lanes were run on the same gel but were noncontiguous. n>=3 per group. **p<0.01, 1w ANOVA, Tukey's correction.

Supplemental Figure 9. *Inhibition of ERK1/2 activation suppresses Smad2 activation in both nonmyocyte and myocyte compartments.* A-B. Labeling index (% positive cells) of pSmad2 or pERK1/2 immunofluorescence in the nonmyocyte and myocyte compartments. n>5 fields per group. C. Total number of nonmyocytes and myocytes normalized to *Fbn1*$^{+/+}$:SHAM data. n=15-30 fields per group. *p<0.05, **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 10. *TGFβ3 is predominantly expressed in the nonmyocyte compartment.* A-C. Representative *in situ* hybridization of *Tgfb3.* A. *Fbn1*$^{+/+}$:TAC vs *Fbn1*$^{C1039G/+}$:TAC, *Tgfb3*, red. Left panel, scale bar: 10µm. Right panel, zoom 2x inset. Dotted line demarcates myocyte compartment. Red arrows point to examples of *in situ* RNA hybridization (red dots) found throughout the nonmyocyte compartment. B. Myocyte- vs nonmyocyte-enriched areas. Scale bar: 10µm. C. *Tgfb3 and Vim.* Left panel, *Tgfb3*, red, left panel and *Vim*, red, right panel. Dotted-line outlines the cardiac myocytes. Scale bar: 10µm. D. mRNA expression of *Tgfb3* and *Vim* normalized to *Gapdh* and then to myocyte data. n=4-6 per group. ***p<0.001, Student's t-test.

Supplemental Figure 11. *AngII-mediated ERK1/2 activation is differentially increased in Fbn1*$^{C1039G/+}$ *vs WT fibroblasts.* Immunoblots for pSmad2, pERK1/2 and GAPDH using cultured neonatal murine cardiac fibroblasts from *Fbn1*$^{C1039G/+}$ and *Fbn1*$^{+/+}$ hearts with AngII (5nM) or TGFß3 (5 ng/ml) stimulation for 12 hours. Lanes were run on the same gel but were noncontiguous. n>=3 per group. ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 1



Supplemental Figure 1. *Fbn1$^{C1039G/+}$ hearts display normal cardiac function in the absence of hemodynamic stress.* A. Echocardiographic quantification of cardiac dimensions and function in *Fbn1$^{+/+}$* and *Fbn1$^{C1039G/+}$* mice with and without valvular regurgitation at 4 and 12 months of age. EDD, end-diastolic diameter; ESD, end-systolic diameter; FS, fractional shortening; LVM, left ventricular mass. n>=14 per group. *p<0.05, **, p<0.01, ***p<0.001, 2w ANOVA, Tukey's correction. B. Representative PV loop of a 12mo *Fbn1$^{+/+}$* (blue line, blue fill) and *Fbn1$^{C1039G/+}$* mouse (red line, red fill) without valvular regurgitation. Summary data obtained from PV loop analysis shown in bar graphs: E_{es}, end-systolic elastance and PRSW, preload recruitable stroke work, reflect load-independent indices of ventricular contractility. Tau, relaxation time constant reflects a load-independent index of ventricular stiffness; n=3-6 per group. C. dP/dt_{max}, peak rate of left ventricular pressure rise, an index of contractility; dP/dt_{min}, peak rate of left ventricular pressure decline, an index of lusitropy. Invasive blood pressure measurements taken from PV loop analysis of *Fbn1$^{+/+}$* and *Fbn1$^{C1039G/+}$* mice without valvular regurgitation at 4 and 12 months of age. n=3-6 per group. D. Gross morphometric analysis of post-natal *Fbn1$^{+/+}$*, *Fbn1$^{C1039G/+}$*, *Fbn1$^{C1039G/C1039G}$* mice at 8do, 6mo and 12mo age, in mice without valvular regurgitation. HW/BW, heart weight/body weight ratio; HW/TL, heart weight/tibial length ratio. n>=4 per group.

Supplemental Figure 2



Supplemental Figure 2. *Fbn1$^{C1039G/+}$ hearts have normal TGFβ signaling in the absence of hemodynamic stress.* A-C. Representative Western blot and summary quantification for phosphorylated/total (p/t), p/tSmad2, p/tERK1/2, and GAPDH using left ventricular tissue lysates. n=4 per group. D. mRNA expression normalized to *18S* and then to *Fbn1$^{+/+}$* data, assessed by real-time RT-PCR from left ventricular tissue of 3mo *Fbn1$^{+/+}$*and *Fbn$^{/C1039G/+}$* hearts without regurgitation. *Ctgf*, connective tissue growth factor. *Serpine1*, plasminogen activator inhibitor, type 1. n>=4 per group.

Supplemental Figure 3



Supplemental Figure 3. *Fbn1$^{C1039G/+}$ hearts develop hypertrophy and fibrosis in response to pressure overload.* A. Baseline echocardiographic quantification of cardiac dimensions in 5mo *Fbn1$^{+/+}$* and *Fbn1$^{C1039G/+}$* mice without valvular regurgitation. EDD, end-diastolic diameter; ESD, end-systolic diameter; IVST, interventricular septum thickness; PWT, posterior wall thickness. n=4-6 per group. B. Myocyte hypertrophy, as assessed by cross-sectional area (CSA) in hematoxylin-eosin staining. Summary quantification of averaged data, >20 cells per heart. n=4 per group. C. Fibrotic area, as assessed by Masson's Trichrome stain and quantified by total number of blue pixels normalized to whole tissue area and then to *Fbn1$^{+/+}$*:SHAM data. n=4-6 per group. D. mRNA expression of hypertrophy genes, normalized to *Gapdh* and then to *Fbn1$^{+/+}$*:SHAM data, assessed by real-time RT-PCR. n=4-6 per group. *Myh7,* myosin heavy chain 7 (βMHC), *Nppa,* natriuretic peptide *A* (ANP), *Nppb,* natriuretic peptide B (BNP). **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 4



Supplemental Figure 4. *Fibrillin-1 protein fails to deposit in myocardium in load-induced heart failure in Fbn1$^{C1039G/+}$ mice.* Additional representative images of immunofluorescent fibrillin-1 staining (red) of heart sections from *Fbn1$^{+/+}$* and *Fbn1$^{C1039G/+}$* mice subjected to 4w TAC. Red, fibrillin-1 (interstitial space); blue, DAPI (nuclei); Green, lipofuscin (myocytes). Top 4 panels, Scale bar: 20 µm. Bottom 4 panels, 2x zoom. White arrow head points to an example nonmyocyte cell in the interstitial space.

Supplemental Figure 5



Supplemental Figure 5. *Smad2 and ERK1/2 activation are differentially increased in the myocyte and nonmyocyte compartments of failing Fbn1$^{C1039G/+}$ hearts.* A. Representative serial sections of pSmad2 (red, top panels) and pERK1/2 (red, bottom panels) immunostaining in *Fbn1*$^{C1039G/+}$ hearts subjected to 4w TAC. Far left panels, scale bar: 50 µm. Middle and far right panels, zoom 2x. Blue, DAPI (nuclei); Green, lipofuscin (myocytes). White arrows, myocyte nuclei. Yellow arrows, nonmyocyte nuclei. B. Summary quantification of % of total pSmad2 and pERK1/2 immunofluorescence intensity localized to nonmyocyte (NM) and myocyte (M) cells per unit area. n=10-15 areas quantified. *p<0.05, **p<0.01, Student's t-test. C. Representative myocyte-enriched serial sections. Scale bar: 50 µm. D. Representative co-immunostaining of serial sections with vimentin (yellow) and pSmad2 (left panel) and vimentin (yellow) and pERK1/2 (right panel). Scale bar: 25 µm. Gray, lipofuscin (myocytes).

Supplemental Figure 6



Supplemental Figure 6. *ERK1/2 activation, but not Smad2 activation, is significantly attenuated by MEK inhibition.* Immunoblot for pSmad2, pERK1/2 and GAPDH using cultured neonatal rat cardiac fibroblasts with TGF-ß3 (10 ng/ml) stimulation for 15 minutes with and without treatment with MEKi, RDEA119 (100nM) or PD98059 (50µM). n=4 per group. **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 7











Supplemental Figure 7. *Myocyte hypertrophy in Fbn1$^{C1039G/+}$hearts is prevented with losartan and MEKi treatment.* A. Representative hematoxylin-eosin staining of formalin-fixed heart sections. White dotted line delineates myocyte diameter. Scale bars: 50μm. B. Myocyte hypertrophy as assessed by wheat germ agglutinin (WGA) staining. Scale bars: 25μm. C. Summary quantification of average cross-sectional area (CSA) data, >1000 cells per heart. n=4-7 per group. D. mRNA expression of hypertrophy genes, normalized to *Gapdh* and then to *Fbn1*$^{+/+}$:SHAM data, assessed by real-time RT-PCR. *Myh7,* myosin heavy chain 7 (βMHC), Myh6, myosin heavy chain 6 (αMHC), *Nppa,* natriuretic peptide *A* (ANP), *Nppb,* natriuretic peptide B (BNP). n=4-7 per group. *p<0.05, **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 8



Supplemental Figure 8. *Smad2 and ERK1/2 activation are differentially increased in response to TGFβ and angiotensin II in cardiac fibroblasts.* Immunoblot for pSmad2, pERK1/2 and GAPDH using cultured neonatal murine cardiac fibroblasts with TGFß1 (5 ng/ml) or AngII (5nM) stimulation for 24 hours. Lanes were run on the same gel but were noncontiguous. n>=3 per group. **p<0.01, 1w ANOVA, Tukey's correction.

Supplemental Figure 9



Supplemental Figure 9. *Inhibition of ERK1/2 activation suppresses Smad2 activation in both nonmyocyte and myocyte compartments.* A-B. Labeling index (% positive cells) of pSmad2 or pERK1/2 immunofluorescence in the nonmyocyte and myocyte compartments. n>5 fields per group. C. Total number of nonmyocytes and myocytes normalized to *Fbn1*$^{+/+}$:SHAM data. n=15-30 fields per group. *p<0.05, **p<0.01, ***p<0.001, 1w ANOVA, Tukey's correction.

Supplemental Figure 10



Supplemental Figure 10. *TGFβ3 is predominantly expressed in the nonmyocyte compartment.* A-C. Representative *in situ* hybridization of *Tgfb3*. A. *Fbn1*$^{+/+}$:TAC vs *Fbn1*$^{C1039G/+}$:TAC, *Tgfb3*, red. Left panel, scale bar: 10µm. Right panel, zoom 2x inset. Dotted line demarcates myocyte compartment. Red arrows point to examples of *in situ* RNA hybridization (red dots) found throughout the nonmyocyte compartment. B. Myocyte- vs nonmyocyte-enriched areas. Scale bar: 10µm. C. *Tgfb3 and Vim.* Left panel, *Tgfb3*, red, left panel and *Vim*, red, right panel. Dotted-line outlines the cardiac myocytes. Scale bar: 10µm. D. mRNA expression of *Tgfb3* and *Vim* normalized to *Gapdh* and then to myocyte data. n=4-6 per group. ***p<0.001, Student's t-test.

Supplemental Figure 11



Supplemental Figure 11. *AngII-mediated ERK1/2 activation is differentially increased in Fbn1$^{C1039G/+}$ vs WT fibroblasts.* Immunoblots for pSmad2, pERK1/2 and GAPDH using cultured neonatal murine cardiac fibroblasts from *Fbn1$^{C1039G/+}$* and *Fbn1$^{+/+}$* hearts with AngII (5nM) or TGFß3 (5 ng/ml) stimulation for 12 hours. Lanes were run on the same gel but were noncontiguous. n>=3 per group. ***p<0.001, 1w ANOVA, Tukey's correction.